<code id='D6EF9CE8B9'></code><style id='D6EF9CE8B9'></style>
    • <acronym id='D6EF9CE8B9'></acronym>
      <center id='D6EF9CE8B9'><center id='D6EF9CE8B9'><tfoot id='D6EF9CE8B9'></tfoot></center><abbr id='D6EF9CE8B9'><dir id='D6EF9CE8B9'><tfoot id='D6EF9CE8B9'></tfoot><noframes id='D6EF9CE8B9'>

    • <optgroup id='D6EF9CE8B9'><strike id='D6EF9CE8B9'><sup id='D6EF9CE8B9'></sup></strike><code id='D6EF9CE8B9'></code></optgroup>
        1. <b id='D6EF9CE8B9'><label id='D6EF9CE8B9'><select id='D6EF9CE8B9'><dt id='D6EF9CE8B9'><span id='D6EF9CE8B9'></span></dt></select></label></b><u id='D6EF9CE8B9'></u>
          <i id='D6EF9CE8B9'><strike id='D6EF9CE8B9'><tt id='D6EF9CE8B9'><pre id='D6EF9CE8B9'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:comprehensive    Page View:524
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In